Reynders Mcveigh Capital Management Has Lifted Abbott Laboratories (ABT) Position; SWISSCOM AG ITTIGEN (SWZCF) Sellers Decreased By 8.84% Their Shorts

January 16, 2018 - By Adrian Mccoy

SWISSCOM AG ITTIGEN (OTCMKTS:SWZCF) had a decrease of 8.84% in short interest. SWZCF’s SI was 982,000 shares in January as released by FINRA. Its down 8.84% from 1.08M shares previously. With 200 avg volume, 4910 days are for SWISSCOM AG ITTIGEN (OTCMKTS:SWZCF)’s short sellers to cover SWZCF’s short positions. It closed at $535 lastly. It is down 0.00% since January 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Reynders Mcveigh Capital Management Llc increased Abbott Laboratories (ABT) stake by 3.58% reported in 2017Q3 SEC filing. Reynders Mcveigh Capital Management Llc acquired 9,169 shares as Abbott Laboratories (ABT)’s stock declined 3.42%. The Reynders Mcveigh Capital Management Llc holds 265,245 shares with $14.15M value, up from 256,076 last quarter. Abbott Laboratories now has $101.83B valuation. The stock decreased 0.58% or $0.34 during the last trading session, reaching $58.5. About 2.05 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since January 16, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

Swisscom AG provides telecommunication services primarily in Switzerland and Italy. The company has market cap of $27.95 billion. It offers broadband, fixed-network, and mobile phone subscription services, as well as national and international telephone, and data traffic services for residential customers, and small and medium-sized enterprises; and value-added and TV services, as well as sells terminal equipment and operates on-line and telephone directories. It has a 16.4 P/E ratio. The firm also provides information and communication technology products and solutions; fixed and mobile networks by other telecommunication service providers; and roaming to foreign operators whose clients use its mobile networks, as well as broadband services and regulated products.

Since August 1, 2017, it had 0 buys, and 6 insider sales for $22.86 million activity. Shares for $5.43M were sold by Salvadori Daniel Gesua Sive. 52,700 Abbott Laboratories (NYSE:ABT) shares with value of $2.74M were sold by Contreras Jaime. $9.73 million worth of stock was sold by Fussell Stephen R on Wednesday, August 16. Bracken Sharon J also sold $98,323 worth of Abbott Laboratories (NYSE:ABT) on Tuesday, August 1.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 92 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Friday, July 21 by Gabelli. The rating was maintained by Cowen & Co on Friday, September 22 with “Buy”. Jefferies maintained it with “Buy” rating and $58.0 target in Tuesday, October 10 report. The rating was maintained by RBC Capital Markets with “Buy” on Friday, September 1. The stock has “Overweight” rating by Barclays Capital on Thursday, October 19. Stifel Nicolaus maintained it with “Buy” rating and $58 target in Thursday, July 23 report. The firm has “Equal-Weight” rating by Morgan Stanley given on Thursday, October 19. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, January 26. RBC Capital Markets has “Outperform” rating and $46 target. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, July 20. The stock of Abbott Laboratories (NYSE:ABT) earned “Market Perform” rating by William Blair on Friday, January 29.

Reynders Mcveigh Capital Management Llc decreased Qualcomm Inc (NASDAQ:QCOM) stake by 76,777 shares to 30,758 valued at $1.59M in 2017Q3. It also reduced Perrigo Co Pcl (NYSE:PRGO) stake by 25,756 shares and now owns 46,088 shares. Johnson Controls Intl Plc was reduced too.

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.01, from 0.88 in 2017Q2. It worsened, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Tompkins Financial Corporation accumulated 24,452 shares. Moreover, Northstar Grp has 0.3% invested in Abbott Laboratories (NYSE:ABT) for 9,595 shares. Holt Capital Advsr Ltd Dba Holt Capital Ltd Partnership holds 0.36% of its portfolio in Abbott Laboratories (NYSE:ABT) for 20,581 shares. Eagle Asset Management Inc reported 1.64M shares. 5,021 are held by Baxter Bros. Lombard Odier Asset Mngmt (Europe) Ltd owns 21,566 shares. Stadion Money Mgmt Ltd Limited Liability Company invested in 0.06% or 36,398 shares. British Columbia Investment Mngmt stated it has 0.3% of its portfolio in Abbott Laboratories (NYSE:ABT). 12.56M were reported by Alliancebernstein Lp. Bath Savings Tru invested 0.79% of its portfolio in Abbott Laboratories (NYSE:ABT). Jennison Associates Limited Com stated it has 0.09% in Abbott Laboratories (NYSE:ABT). Covington Inv Advsrs reported 0.76% in Abbott Laboratories (NYSE:ABT). X Llc reported 6,736 shares or 0.01% of all its holdings. 10.95M are held by Tiaa Cref Invest Mngmt Ltd. Webster Financial Bank N A owns 9,843 shares or 0.08% of their US portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: